Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome

Rhea-AI Summary

Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome. This designation, based on positive clinical outcomes in Germany, allows Kyverna to receive expert guidance on efficient drug development and use of surrogate endpoints from senior FDA officials. The company is set to begin its sponsored trial, KYSA-8, which could potentially revolutionize SPS treatment by offering a durable, immunosuppressant-free remission through an immunological reset of the patient's immune system.

Positive

• Received FDA RMAT designation for KYV-101 in treating refractory stiff-person syndrome
• Positive clinical outcomes observed in patients treated in Germany
• RMAT designation allows for expert guidance from senior FDA officials on efficient drug development
• Potential for paradigm-shifting treatment offering durable, immunosuppressant-free remission

Negative

• None.

Insights

Medical Research Analyst

The RMAT designation for Kyverna's KYV-101 signals remarkable progress in the field of regenerative medicine, particularly for treating refractory stiff-person syndrome (SPS), a rare and debilitating autoimmune disorder. The FDA's RMAT status aims to expedite the development and review processes for promising therapies that address serious or life-threatening conditions. This is especially relevant for KYV-101, given its innovative approach using CD19 chimeric antigen receptor (CAR) T-cell technology.

RMAT designation will provide Kyverna with access to senior FDA officials and guidance on how to efficiently navigate the regulatory landscape. This should significantly speed up KYV-101's path to market, potentially leading to quicker access for patients who are in dire need of new treatment options. Importantly, the FDA's willingness to provide such a designation is often seen as a vote of confidence in the preliminary data from early clinical trials, reinforcing the potential efficacy and safety of KYV-101.

Market Research Analyst

The RMAT designation could have a considerable impact on Kyverna's market position and overall valuation. From an investor's standpoint, this development places Kyverna in a favorable light within the biopharmaceutical industry, highlighting its pioneering position in the realm of cell therapy for autoimmune diseases. The recognition from the FDA can attract increased interest from institutional investors and potential pharmaceutical partners, looking to collaborate or invest in cutting-edge therapeutic options.

While the RMAT status does not guarantee eventual FDA approval, it does provide an avenue for accelerated development and review processes, which can translate to significant cost and time efficiencies. For retail investors, this means that Kyverna's stock might experience positive momentum as the company progresses through its clinical trials and regulatory milestones.

The application was evaluated based on the positive clinical outcomes of KYV-101 in patients treated in Germany under a named-patient treatment option

The Regenerative Medicine Advanced Therapies designation will allow Kyverna to receive expert guidance on efficient drug development and use of surrogate endpoints from senior FDA officials

EMERYVILLE, Calif., July 15, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today the designation as Regenerative Medicine Advanced Therapy (RMAT) by the U.S. Food and Drug Administration (FDA) for its autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate, KYV-101, to be used for the treatment of patients suffering from refractory stiff-person syndrome. 

"Stiff-person syndrome has devastating and life-altering effects on patients suffering from this rare autoimmune disease," said Amanda Piquet, M.D., director of the Autoimmune Neurology Program at CU Anschutz Medical Campus, Aurora, CO. "I look forward to the data that will emerge from the KYSA-8 trial as this trial could drastically change the treatment landscape for SPS."

"We are eager to begin generating data from our sponsored trial to advance the knowledge on a potential immunological reset of the patient's immune system," said Peter Maag, Ph.D., chief executive officer at Kyverna. "We are humbled by the resilience of the SPS patients and their hope for a potential paradigm-shifting treatment option that could provide durable, immunosuppressant-free remission."

About Stiff Person Syndrome (SPS) 
SPS is a rare, progressive neurological autoimmune disorder causing debilitating muscle stiffness in the torso, arms, and legs, impacting the ability to walk or move. Patients typically present with muscle spasms and stiffness, resulting in difficulty turning and bending. When stiffness is severe, the patients' posture resembles a statue. Muscle spasms and stiffness can be precipitated by unexpected stimuli, including sounds, like a phone ring or a siren, sudden touches or conditions triggering anxiety and emotional upset which, when severe, are misdiagnosed as a primary anxiety disorder¹. 

About KYV-101
KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate for use in B cell-driven autoimmune diseases. The CAR in KYV-101 was designed by the National Institutes of Health (NIH) to improve tolerability and tested in a 20-patient Phase 1 trial in oncology. Results were published by the NIH in Nature Medicine².

KYV-101 is currently being evaluated in sponsored, open-label, Phase 1/2 and Phase 2 trials of KYV-101 in the United States and Germany across two broad areas of autoimmune disease: rheumatology and neurology.

With 50 patients treated so far with the CAR in KYV-101 in both oncological and autoimmune conditions at more than 15 locations in Europe and the U.S., we believe that the differentiated properties of KYV-101 are critical for the potential success of CAR T cells as autoimmune disease therapies.

KYV-101 is also being evaluated in investigator-initiated trials for multiple indications in multiple geographies.

About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. 

Our lead CAR T-cell therapy candidate, KYV-101 is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. 

Kyverna's pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: the potential impact of named-patient case studies; Kyverna's goals to develop certain paradigm-shifting treatment options; Kyverna's beliefs about the differentiated properties of KYV-101; and Kyverna's clinical trials. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of Kyverna's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna's management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. 

For more information, please visit https://kyvernatx.com. 

Investor Contact:
George Thampy
Kyverna Therapeutics
InvestorRelations@kyvernatx.com 

Kyverna Media Contact:
Consort Partners for Kyverna
kyvernatx@consortpartners.com 

¹ Dalakas, M.C., Neurotherapeutics 2022; 19, 832–847.
² Brudno et al., Nature Medicine 2020; 26:270-280. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/kyvernas-kyv-101-receives-us-fda-rmat-designation-for-kyv-101-in-the-treatment-of-patients-with-refractory-stiff-person-syndrome-302197289.html

SOURCE Kyverna Therapeutics

FAQ

What is the RMAT designation Kyverna Therapeutics (KYTX) received for KYV-101?

Kyverna Therapeutics received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome.

What are the potential benefits of KYV-101 for stiff-person syndrome patients?

KYV-101 could potentially offer a paradigm-shifting treatment for stiff-person syndrome, providing durable, immunosuppressant-free remission through an immunological reset of the patient's immune system.

What is the name of Kyverna Therapeutics' (KYTX) upcoming clinical trial for KYV-101?

Kyverna Therapeutics' upcoming clinical trial for KYV-101 in treating stiff-person syndrome is called KYSA-8.

How does the RMAT designation benefit Kyverna Therapeutics (KYTX) in developing KYV-101?

The RMAT designation allows Kyverna to receive expert guidance on efficient drug development and use of surrogate endpoints from senior FDA officials, potentially accelerating the development process.